pharmaphorum

OCTOBER 12, 2021

A data-mining study conducted by researchers in the US has found that an already-approved diuretic drug could have potential as a treatment for some patients with Alzheimer’s disease.

Gene Expression 111

Gene Expression Drugs FDA Approval Gene 111

Scienmag

SEPTEMBER 23, 2021

One of the challenges in the era of Big Data is dealing with many independent variables, also known as the ‘curse of dimensionality’. To address this issue, computer scientists at the University […].

Big Data 52

Big Data Scientist Development 52

Scienmag

SEPTEMBER 8, 2020

AMES, Iowa — An Iowa State University research project to understand how shrinking small towns maintain quality of life has received another major grant to expand the team’s work. The rural smart shrinkage project, led by Kimberly Zarecor, professor of architecture, received a three-year, $1.5

Big Data 44

Big Data Research Scientist 44

pharmaphorum

FEBRUARY 1, 2022

His research focuses on the development of big data machine learning for tracking the health of complex systems. David Clifton is professor of clinical machine learning in the Department of Engineering Science of the University of Oxford.

Clinical Trials 104

Clinical Trials Clinical Trials Trials Engineer 104

pharmaphorum

JANUARY 24, 2022

AI in drug discovery is becoming an integral part of the research and development area of treating diseases with more companies incorporating ‘Big Data’ and data scientists within their R&D teams. Discuss the impact of big data and how it applies to AI drug discovery within Pharma. Who Should Attend?

Drugs 52

Drugs Big Data Scientist Clinical Trials 52

XTalks

APRIL 5, 2021

Bioinformaticians use a combination of mathematics, computer science and biology to help scientists make sense of the data gathered from research projects. The findings gathered are then documented and presented to a larger audience, whether to scientists in the lab or at conferences. Bioinformatics Scientist.

Bioinformatics 59

Bioinformatics Engineer Scientist Genomics 59

pharmaphorum

DECEMBER 14, 2020

Part of the foremost conference series for microbiome researchers in industry, the 5th Microbiome Movement – Drug Development Europe 2021 will return to unite leading scientists from the biopharmaceutical and academic community to pursue the causal role of the microbiome in disease, and help create a new generation of microbiome-targeted therapeutics (..)

Development 52

Development Drugs Big Data Genome 52

pharmaphorum

FEBRUARY 11, 2022

Therefore, organisations can determine how they’d like to use the Map’s data then create a software solution that helps them do so. This technology can be particularly beneficial for rare disease organisations as they often don’t have data scientists at their disposal or full-stack engineers. About the author.

Life Science 105

Life Science Engineer Development Big Data 105

Sciensano

JULY 16, 2024

Mahsa Shabani (Ugent) “Towards the implementation of the EHDS across member states: expected challenges and opportunities” Case study End-of-Life-Care data linkage by Prof.

Research 52

Research Big Data Scientist Development 52

pharmaphorum

FEBRUARY 16, 2021

Consequently, the commercial teams would never have access to the detailed R&D data or the production data, making it impossible to have an end-to-end management of the product life cycle based on a common dataset. Once we combine data-driven and human behavioural insights, we can really understand what we can do.

Marketing 107

Marketing Production Big Data Pharma Companies 107

XTalks

AUGUST 2, 2023

Last year, Novo Nordisk forged extensive global partnerships, which included teaming up with Microsoft to leverage AI and big data technology to expedite its research. It was founded in 2008 by Dr. Ugur Sahin and Dr. Özlem Türeci, a husband-and-wife team of scientists and physicians.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JANUARY 17, 2021

Syntegra has also engaged with the Federal Drug Administration (FDA) to evaluate the role of synthetic data in regulatory decisions, for COVID-19 and beyond. With the COVID-19 pandemic, there has never been a time when rapid, low burden access to patient-level data, at scale, was more urgent” says Michael D. .”

Life Science 52

Life Science Engineer Big Data Scientist 52